Inside USP: Traditional Chinese Medicines and Western Regulatory Paradigms - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside USP: Traditional Chinese Medicines and Western Regulatory Paradigms
Traditional Chinese Medicine is widely used, but questions persist regarding its regulatory status.

Pharmaceutical Technology
Volume 33, Issue 7, pp. 64-66

Options under the Dietary Supplement Health and Education Act

The complex regulatory status of TCM suggests parallels with dietary supplements and dietary supplement ingredients. Americans and other Western consumers typically link TCM herbal ingredients with dietary supplement herbal ingredients. Health food stores or the dietary supplement aisles at drug or grocery stores include a wide variety of botanicals, both in raw form and in concentrated or extracted fractions.

Current regulations for dietary supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA) provide the lowest barrier to market entry (5). In brief, submission of a new dietary ingredient (NDI) to FDA's Office of Nutritional Products, Labeling, and Dietary Supplements (ONPLDS) as a Notification (NDIN) requires a safety data package that is relatively straightforward.

DSHEA states that a dietary supplement that contains an NDI shall be deemed adulterated under section 402(f) of the Act [21 USC 342(f)] unless it meets one of two requirements: the dietary supplement contains only dietary ingredients that have been present in the food supply as an article used for food in a form in which the food has not been chemically altered; or a history of use or other evidence of safety establishes that the dietary ingredient when used under the conditions recommended or suggested in the labeling of the dietary supplement will reasonably be expected to be safe. Further, the manufacturer or distributor of the dietary ingredient or dietary supplement must provide FDA with certain safety information. Such safety information can include citations to published articles on the basis of which the manufacturer or distributor has concluded that a dietary supplement containing the dietary ingredient can reasonably be expected to be safe.

If a dietary ingredient has not been present in the food supply, vendors must show why they believe that consumption of an NDI can reasonably be expected to be safe under the conditions recommended in the labeling. FDA has not published guidance defining the specific information required to demonstrate safety but has made clear its position that there should be a "reasonable expectation of safety" when the product is used. The manufacturer is therefore responsible for determining what information provides the basis for the safety conclusion.

Standards for TCM–USP's role

Standardization of any new ingredient is of paramount importance. Appropriate specifications to demonstrate quality and purity (and impurities at acceptable levels) are critical in obtaining a successful response from a GRAS Expert Panel, from FDA's Center for Food Safety and Applied Nutrition during a follow-up GRAS Notification, or from ONPLDS in response to an NDIN.

Since its inception, USP has worked to provide accurate names for medicinal products, standardized procedures to test them, and reference standards that independent parties can use to ensure their identity, strength, and purity (1). In modern times, USP has asserted that "the elements of the monograph are sufficient to identify the compendial article and to control its quality in the marketplace. The activity can bring a private consensus developed between a regulatory agency and applicant into the open and allows public scrutiny and endorsement" (6). USP's expanding catalog of official reference standards enables dietary supplement, food ingredient, and pharmaceutical scientists worldwide to test an article in commerce against a reference standard or certified reference standard to ensure that the product is not adulterated (7).

USP also verifies the identity, strength, purity, and quality of dietary supplement finished products, dietary supplement ingredients, and pharmaceutical ingredients. Products and ingredients that pass USP verification requirements—including a GMP audit, product and ingredient testing, and manufacturing documentation review—are awarded use of the USP Verified mark, which helps assure consumers that products provide the expected value.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here